1. Scrip
  3. >>Clinical Trials

Bavarian Drops RSV Program After Phase III Flop

Shifts Focus To Chikungunya

 
• By Ayisha Sharma

The Danish firm’s respiratory syncytial vaccine disappointed in a Phase III trial, marking an unexpected setback after a year of mpox-related successes, prompting all eyes to turn towards a recently-acquired chikungunya vaccine program.  

neon red exit sign against sunset sky
Bavarian Is Leaving The RSV Space After An Unexpected Disappointment • Source: Shutterstock
Key Takeaways:

  • MVA-N RSV showed some efficacy but missed significance in the co-primary endpoint.

  • Hopes have shifted to a Phase III chikungunya vaccine acquired from Emergent BioSolutions.

  • The discontinuation leaves Pfizer and GSK to dominate the RSV jab space for the year ahead.

Bavarian Nordic A/S’s respiratory syncytial virus (RSV) vaccine candidate, MVA-BN RSV, has missed the mark in the Phase III VANIR trial in older adults, but the firm is confident it can meet its financial

VANIR randomized more than 20,000 people aged 60 or older to a single dose of MVA-BN RSV or placebo, measuring the primary endpoint of occurrence of lower-respiratory tract

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D